Januvia 50mg Tablet contains Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the management of type 2 diabetes mellitus. Sitagliptin works by enhancing the levels of incretin hormones, which increase insulin release from pancreatic beta cells and decrease glucagon secretion from alpha cells in a glucose-dependent manner, thereby improving glycemic control. Januvia is prescribed as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, either as monotherapy or in combination with other antidiabetic agents such as metformin, sulfonylureas, or insulin. The recommended dose is 50mg once daily, with or without food. It is important to monitor renal function prior to initiation and periodically during therapy, as dose adjustments may be necessary in patients with renal impairment. Common adverse effects include nasopharyngitis, headache, and upper respiratory tract infections, while hypoglycemia risk increases when used with sulfonylureas or insulin. Januvia is contraindicated in patients with type 1 diabetes or diabetic ketoacidosis. Caution is advised in patients with a history of pancreatitis. Overall, Januvia offers a convenient and effective option for improving glycemic control in type 2 diabetes patients.